The latest trading session saw Johnson & Johnson (JNJ) ending at $152.51, denoting a -0.44% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily loss of 0.04%.

Johnson & Johnson (NYSE:JNJ) responded with disappointment, claiming its actions were pro-competitive and aimed at ensuring patient safety. The company is weighing an appeal. The landmark verdict ...

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Multi-Factor Investor model based on the published strategy ...

ANTARA/HO-Dokumentasi Rumah Sakit Jakarta (ANTARA) - BPJS Kesehatan memastikan bahwa pasien dalam kondisi gawat darurat wajib mendapatkan layanan di rumah sakit, dengan mekanisme pelayanan ...

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Multi-Factor Investor model based on the published strategy ...

Bisnis.com, JAKARTA – Klaim program Jaminan Kesehatan Nasional (JKN) yang harus dibayar Badan Penyelenggara Jaminan Sosial (BPJS) Kesehatan meningkat dibarengi dengan penurunan ketahanan Dana ...

On a special episode (first released on May 21, 2025) of The Excerpt podcast: For generations of Americans, the Johnson & Johnson brand has been a beloved one, as quintessentially American as ...

Hello everyone, I am Shagun Singh, Senior Research Analyst at RBC, and I'm very happy to host the next session with Johnson & Johnson. Joining us from the company is Joe Wolk, Chief Financial ...

I maintain my buy rating on JNJ, citing attractive valuation, improved technicals, and a raised intrinsic value target of $184 per share. JNJ's recent earnings beat expectations, with strong ...